Zhejiang Hisoar Pharmaceutical Co., Ltd is a public company listed on stock exchange in Shenzhen with stock code#002099(hereinafter referred to as “Hisoar Pharma”). The Headquarter is located in Taizhou City, Zhejiang Province. After the successful reforming between Hisoar Pharma and Taizhou Qianjing Chemical under Dankong Group in 2014, Hisoar Pharma has become a new-type listed company integrated with Pharmaceutical and dyestuff. Hisoar Pharmaceutical consists of Zhejiang Hisoar Chuannan Pharmaceutical Co., Ltd., Shanghai Hisoar Pharmaceutical Technology Development Co., Ltd., and Genevida GmbH etc. Hisoar Pharmaceutical focuses on the business of Finish dosage forms, and APIs in respect of antibiotics, cardiovascular, hypoglycemic and fine chemical etc., more than 70% of products are exported. We are the leading global supplier on Clindamycin APIs and have rich experience in contract manufacturing and cooperating with multinational Pharmaceutical corporations. A good reputation and trust have been built during cooperation with world-known Pharmaceutical companies. Hisoar Pharma is paying great attention to the quality system development and achieving excellence, our impeccable adherence to GMP is recognized by approval from US FDA, EDQM, PMDA, TGA and China FDA etc., with dozens of products registered with US FDA, and granted with EU CEP (COS) certification. In the meantime, our adherence to EHS requirement has been granted with ISO14001, OHSAS18001 certification. Production and development base 4 manufacturing sites in China, 1 subsidiary in EU 2 R&D centers (Shanghai, Taizhou) R&D platform: Zhejiang Hisoar Pharmaceutical research institute, National postdoctoral research station, Zhejiang academician expert workstation, and so on.